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Summary
 
The effectiveness of interleukin 10 (IL-10) in the treatment of autoimmune-mediated central
nervous system inflammation is controversial. Studies of the model system, experimental auto-
immune encephalomyelitis (EAE), using various routes, regimens, and delivery methods of
IL-10 suggest that these variables may affect its immunoregulatory function. To study the influ-
ence of these factors on IL-10 regulation of EAE pathogenesis, we have analyzed transgenic
mice expressing human IL-10 (hIL-10) transgene under the control of a class II major histo-
compatibility complex (MHC) promoter. The hIL-10 transgenic mice are highly resistant to
EAE induced by active immunization, and this resistance appears to be mediated by suppres-
sion of autoreactive T cell function. Myelin-reactive T helper 1 cells are induced but non-
 
pathogenic in the IL-10 transgenic mice. Antibody depletion confirmed that EAE resistance is
dependent on the presence of the transgenic IL-10. Mice expressing the hIL-10 transgene
but not the endogenous murine IL-10 gene demonstrated that transgenic IL-10 from MHC
class II–expressing cells is sufficient to block induction of EAE. This study demonstrates that
IL-10 can prevent EAE completely if present at appropriate levels and times during disease in-
duction.
Key words: major histocompatibility complex class II promoter–regulated interleukin 10 • 
myelin-reactive T cells • immune regulation • autoimmunity
 
I
 
L-10 is an immune regulatory factor that has potential
therapeutic value for organ-specific autoimmune diseases
(1). Administration of rIL-10 reduces disease in experimen-
tal models of diabetes, rheumatoid arthritis, and inflamma-
tory bowel disease (2–6); however, its utility in autoim-
mune encephalomyelitis is unclear. Studies using various
routes, regimens, and delivery methods of rIL-10 have
yielded conflicting results. In an adoptive transfer model of
experimental autoimmune encephalomyelitis (EAE), intra-
venous injection of rIL-10 exacerbated rather than sup-
pressed disease (7). In contrast, subcutaneous rIL-10 treat-
ment partially inhibited disease in rat and mouse models of
EAE induced by active immunization (8, 9). In these active
immunization models, daily rIL-10 treatment regimens
from the day of immunization to just before the expected
day of disease onset were necessary for significant EAE in-
hibition. These results suggest that systemic rIL-10 treat-
ment may inhibit EAE either by suppressing in vivo devel-
opment or migration of encephalitogenic Th1 cells or by
inhibiting the inflammatory effector function of these Th1
cells. Recent studies of targeted delivery of IL-10 to the
central nervous system (CNS) have also yielded conflicting
results. Intracranial injection of soluble rIL-10 or plasmids
containing a retroviral promoter–directed IL-10 cDNA at
day 12 after active immunization did not suppress EAE
(10). Adoptive transfer of retroviral transduced myelin basic
protein (MBP)–specific T cell hybridoma also did not in-
hibit EAE (11). In contrast, antigen-inducible IL-10 pro-
duced by proteolipid protein (PLP)-specific T memory
cells suppressed EAE when adoptively transferred to PLP
peptide–immunized mice 1 d before expected disease onset
(12). These results suggest that the timing of IL-10 pro-
duction and possibly the localization of IL-10 may criti-
cally affect its immunoregulatory function.
To study the influence of these factors on IL-10 regula-
tion of EAE pathogenesis, we have analyzed transgenic
mice expressing human IL-10 (hIL-10) under the control
of a class II MHC promoter. hIL-10 is fully active in mice 
1006
 
Transgenic IL-10 Inhibits EAE
 
(1), and the species difference allows for the specific detec-
tion and depletion of transgenic and endogenous IL-10. In
the present study, we have demonstrated that hIL-10 trans-
genic (hIL-10Tg) mice are resistant to EAE induced by ac-
tive immunization and that this resistance is a consequence
of a reduced autoreactive Th1 response.
 
Materials and Methods
 
Mice.
 
SJL/J and CSJLF1/J mice were obtained from The
Jackson Laboratory. BALB/cAnN mice were obtained from
Taconic Farms, Inc. hIL-10Tg mice were constructed using a
hIL-10 cDNA sequence regulated by a class II MHC E
 
a
 
 pro-
moter sequence (13). For this study, male hemizygous BALB/c
IL-10Tg mice were backcrossed with female BALB/cAnN mice
to generate hIL-10Tg and nonTg littermates. SJL 
 
3
 
 BALB/c F1
transgene–positive and nonTg littermates were generated by
crossing male hemizygous hIL-10Tg BALB/cAnN mice with fe-
male SJL/J mice. To generate mice expressing the hIL-10 trans-
gene but lacking endogenous murine IL-10, the hIL-10 transgene
was backcrossed onto the BALB/cAnN IL-10KO background.
Male BALB/cAnN hemizygous hIL-10Tg IL-10KO mice were
bred with female BALB/cAnN IL-10KO mice to produce trans-
gene-positive and nonTg littermate mice on the IL-10KO back-
ground.
 
Induction of EAE.
 
Mouse spinal cord homogenate (MSCH)
was prepared from 8–12-wk-old BALB/cAnN mice as previ-
ously described (14). Bovine MBP was obtained from Sigma
Chemical Co. For active induction of EAE, mice were immu-
nized intradermally with 2.5 mg of MSCH and 200 
 
m
 
g of 
 
Myco-
bacterium tuberculosis
 
 (strain H37RA; Difco) at days 0 and 7 as de-
scribed (14). Mice were examined and scored for clinical signs of
EAE, and routine histopathological analyses of hematoxylin and
eosin– or Luxol fast blue–stained paraffin sections were per-
formed in a masked fashion as described (14).
 
Antibodies.
 
All mAb were purified by column chromatogra-
phy from either ascites fluid or tissue culture supernatants and
contained 
 
,
 
4 EU endotoxin/mg protein. 1B1.2 is a blocking
mAb reactive with mouse IL-10 receptor used in in vitro cultures
(15). The following mAbs were used in vivo: JES3-9D7 (rat
IgG1), a hIL-10–specific mAb that does not cross-react with
mouse IL-10 (16); and GL113 (rat IgG1), an isotype control mAb
reactive with 
 
b
 
-galactosidase. For in vivo mAb treatment, mice
were injected i.p. with 1 mg mAb/dose in 100 
 
m
 
l of PBS. Each
animal received three injections, once per week.
 
Cell Purification.
 
CD4
 
1
 
 draining lymph node (DLN) cells
were purified by positive selection using MACS
 
®
 
 L3T4 micro-
 
beads and MiniMACS
 
®
 
 columns (Miltenyi Biotec). The micro-
bead-labeled cell suspensions were processed through the mag-
netic column twice, and the purity was routinely 
 
.
 
95% CD4
 
1
 
cells. To prepare T cell–depleted APC, spleen cells from naive
CSJLF1/J mice were depleted of CD4 (GK1.5, 20 
 
m
 
g/ml)- and
CD8 (2–43, 20 
 
m
 
g/ml)-staining cells by negative selection using
anti–rat Ig-coated Dynabeads (Dynal).
 
Cell Culture and Cytokine Detection.
 
Mice were immunized
with MSCH following the same procedure as for active induc-
tion of EAE. 10 d after immunization, DLN cells (4 
 
3
 
 10
 
6
 
/ml)
and purified CD4
 
1
 
 DLN cells (10
 
6
 
/ml) were stimulated with 50
 
m
 
g/ml of MBP as described (14). Anti–IL-10 receptor mAb
(1B1.2, 10 
 
m
 
g/ml) was added to cultures where indicated. Cul-
ture supernatants were harvested after 60 h and levels of IFN-
 
g
 
and IL-4 were determined using a sandwich ELISA technique as
described (14).
 
Results
 
Transgenic IL-10 Prevents Induction of EAE.
 
For the ini-
tial study, hIL-10Tg mice and nonTg littermate controls
on the BALB/cAnN genetic background were compared
for EAE susceptibility. Although BALB/c mice are gener-
ally considered to be EAE resistant, it has been reported
that BALB/cAnN and BALB/cByJ substrains are suscepti-
ble to actively induced EAE (17). Consistent with these
results, EAE was reproducibly induced in these strains of
mice by intradermal immunization on days 0 and 7 with
MSCH in CFA (84%, 
 
n
 
 
 
5
 
 86; average EAE grade 
 
5
 
 3.2;
day of disease onset 
 
5
 
 17–30 d after immunization). With
this immunization, hIL-10Tg mice were completely EAE
resistant (0/23 mice), whereas control littermate mice were
highly EAE susceptible and exhibited the same EAE severity
as wild-type BALB/cAnN and SJL/J mice (Fig. 1, A and B).
No inflammatory infiltrates were found in the spinal cords of
EAE-resistant Tg mice, whereas intense inflammatory infil-
trates and demyelination were found in the white matter of
EAE-susceptible nonTg littermate mice (Fig. 2).
To confirm these findings in a more conventional model
of EAE, hemizygous male BALB/c hIL-10Tg mice were
crossed with SJL/J mice to generate transgene-positive
and nonTg littermates. These F1 mice were compared to
CSJLF1/J, which have a highly predictable disease onset at
14 d after immunization with MSCH and a relatively
strong in vitro recall response to MBP. Transgene-positive
Figure 1. hIL-10Tg mice are
EAE resistant. (A) Circles repre-
sent peak severity of clinical dis-
ease for individual mice on the
indicated genetic backgrounds.
Data compiled from three sepa-
rate experiments. (B) Average se-
verity score for hIL-10Tg mice
on the BALB/cAnN background.
One representative experiment of
five is shown. (C) Average sever-
ity score for hIL-10Tg mice on
SJL/J 3 BALB/cAnN F1 back-
ground. One representative ex-
periment of four is shown. 
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SJL/J 
 
3
 
 BALB/cAnN F1 mice had a low EAE incidence
(4/55 mice) and disease severity compared to nonTg litter-
mate control mice (43/46 mice), which were highly sus-
ceptible to EAE. The nonTg littermates exhibited an EAE
severity and disease course similar to wild-type CSJLF1/J
mice (Fig. 1 C). No difference in EAE severity or day of
disease onset was observed when comparing CSJLF1/J
with SJL/J mice (data not shown).
 
Transgenic IL-10 Must Be Present during the Induction of
Disease to Prevent EAE.
 
To show that disease resistance
was due to the direct effects of the transgenic IL-10, immu-
nized transgenic SJL/J 
 
3
 
 BALB/cAnN F1 mice were in-
jected with either JES3-9D7 mAb (hIL-10–specific mAb
[16] that does not cross-react with mouse IL-10) or GL113
mAb (an isotype-matched mAb control). Tg mice receiv-
ing the first anti–hIL-10 mAb injection on the day of im-
munization were susceptible to EAE, whereas the isotype
control mAb–injected mice were resistant to EAE (Fig. 3
A). This result suggests that EAE resistance of hIL-10Tg
mice was the consequence of hIL-10 present during immu-
nization, rather than of developmental effects of the trans-
gene. A consistent delay in the day of disease onset was
found in the anti–hIL-10 mAb–treated mice compared to
 
control littermates (Fig. 3 A). To determine the cause of
this delay, anti–hIL-10 mAb treatment was initiated 8 d be-
fore MSCH immunization. With this treatment regimen,
the EAE clinical grade and day of disease onset for hIL-10Tg
and control littermate mice were indistinguishable (Fig. 3 B).
Similar results were obtained when hIL-10Tg mice on the
BALB/cAnN genetic background were treated with the
anti–hIL-10 mAb (data not shown).
 
MBP-specific Th1 Cells Were Generated Normally in IL-10Tg
Mice.
 
Three possible mechanisms for the regulatory effect
of IL-10Tg in EAE are as follows: inhibition of the initial
development of autoreactive Th1 cells, active inhibition of
Th1 cells by IL-10, or immune deviation toward a Th2-type
response. To test these, the cytokine secretion profiles of
DLN cells from MSCH-immunized SJL 
 
3
 
 BALB/c F1
hIL-10Tg and control littermate mice were analyzed. 10 d
after immunization, DLN cells were prepared for culture in
the presence of MBP or MBP plus anti–IL-10 receptor
mAb. After 3 d, the culture supernatants were tested for se-
creted IFN-
 
g
 
 and IL-4. Cells from nonTg littermate mice
stimulated with MBP secreted higher levels of IFN-
 
g
 
 than
cells from Tg mice, a result consistent with the association
of EAE pathogenesis with IFN-
 
g
 
 production (Fig. 4).
However, when stimulated with MBP in the presence of
anti–IL-10 receptor mAb, cells from both hIL-10Tg mice
and littermate controls produced similar levels of IFN-
 
g
 
.
To eliminate APC differences between hIL-10Tg and
control littermate mice, CD4
 
1
 
 T cells were purified and
cultured with irradiated, T-depleted splenocytes from
CSJLF1/J donor mice. In the absence of APC-derived
hIL-10Tg, T cells from both hIL-10Tg and control litter-
mate mice produced equivalent levels of IFN-
 
g
 
 (Fig. 4 B).
No MBP-specific IL-4 production was detected in cultures
of DLN cells or CD4
 
1
 
 T cells from hIL-10Tg or control
littermate mice, suggesting that EAE resistance in the Tg
mice was not associated with a Th2-type response (data not
shown). These results support the interpretation that mye-
lin-reactive Th1 cells were induced in the hIL-10Tg mice
and suggest that their ability to exert an effector function
was actively suppressed by IL-10 in vivo.
 
hIL-10Tg in the Absence of Endogenous Mouse IL-10 Can
Prevent EAE.
 
To assess whether T cell–derived endogenous
mouse IL-10 was required for EAE resistance, the IL-10Tg
mice were backcrossed onto an IL-10 null (IL-10KO)
background to generate mice that expressed hIL-10Tg but
Figure 2. Histology of spinal cords of hIL-10Tg mice and nonTg lit-
termates immunized to induce EAE. (A) hIL-10Tg mice were EAE resis-
tant and spinal cords showed no inflammatory infiltrates or plaques of de-
myelination in the white matter (normal white matter outlined by
arrows). (B) NonTg littermates were highly EAE susceptible and showed
inflammatory infiltrates and extensive demyelination in the white matter.
Luxol fast blue stain with hematoxylin counterstain. 3125.
Figure 3. Induction of EAE in
hIL-10Tg mice treated with anti–
hIL-10 mAb. Days of mAb treatment
are indicated by arrows. (A) Tg mice
were injected with anti–hIL-10 mAb
(1 mg/dose) or isotype-matched mAb
starting at the day of MSCH immu-
nization. One representative experi-
ment out of five is shown. (B) Mice
were injected with the mAb starting
8 d before MSCH immunization.
One representative experiment out
of three is shown. 
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lacked endogenous mouse IL-10. Because murine T cells
do not express MHC class II molecules, no T cell–derived
IL-10 is present in these mice. The hIL-10Tg IL-10KO
mice and nonTg IL-10KO littermates were tested for sus-
ceptibility to EAE. Transgene-positive IL-10KO mice,
which only have MHC class II–positive cell–derived IL-10,
were completely resistant to EAE, whereas nonTg IL-10KO
littermates were highly susceptible to EAE (Fig. 5). No dif-
ference in EAE susceptibility was observed when nonTg
IL-10KO littermates were compared with BALB/cAnN
IL-10KO mice (data not shown). Treatment with anti–
hIL-10 mAb reversed this protection in the Tg IL-10KO
mice, which became as susceptible to EAE as nonTg
IL-10KO littermates (Fig. 5). To determine the extent of
the protection provided by the IL-10Tg in the absence of
endogenous murine IL-10, the CNS of the three groups
of mice from Fig. 5 were examined. Intense inflammatory
infiltrates and extensive demyelination as determined by
the loss of Luxol fast blue staining were found in the white
matter of nonTg IL-10KO littermates, consistent with the
clinical disease (Fig. 6 A). In contrast, the CNS of the
EAE-resistant mice expressing the IL-10 transgene but
lacking endogenous murine IL-10 were completely free of
inflammatory infiltrates and demyelination (Fig. 6 B). Exam-
ination of the CNS of hIL-10 transgene–positive IL-10KO
mice treated with anti–hIL-10 mAb showed extensive in-
flammation and demyelination similar to the pathological
changes found in the nonTg littermates (data not shown).
These data suggest that APC production of IL-10 alone,
despite the complete absence of T cell–produced IL-10, is
sufficient to protect mice from EAE.
 
Discussion
 
In this study, we have demonstrated that Tg mice ex-
pressing hIL-10 under the control of the MHC class II pro-
moter are completely resistant to induction of EAE and
that this resistance is independent of T cell–derived IL-10.
The use of human IL-10, which has similar specific activity
to murine IL-10 (1, 2), allowed for the specific measurement
and inhibition of Tg and endogenous IL-10. Treatment of
MSCH-immunized mice with neutralizing anti–hIL-10 at
the time of immunization rendered transgene-positive mice
fully susceptible to EAE, although the disease onset was
delayed by several days (Figs. 3 and 5). Treatment of
hIL-10Tg mice with anti–hIL-10 mAb 8 d before MSCH
immunization resulted in kinetics of disease onset identical
to that of nonTg littermates, suggesting that the elevated
IL-10 level before immunization can also influence the re-
sponse to antigen, consistent with our previous study show-
ing that IL-10 has significant effects on the function of
APC prior to antigen-induced activation (18). Further-
more, APC-derived IL-10Tg is sufficient for EAE pre-
vention, as shown by the resistance of transgene-positive
BALB/c mice homozygous for a mutated mouse IL-10
gene (Fig. 5). Therefore, IL-10 need not be provided by T
cells to prevent EAE.
Figure 4. MBP-specific Th1
cells are induced in hIL-10Tg
mice. hIL-10Tg mice (black bar)
and control littermate mice (gray
bar) were immunized twice at
1-wk intervals with MSCH emul-
sified in CFA. (A) 3 d after the
last immunization, DLN cells
from hIL-10Tg or control litter-
mate mice were stimulated with
MBP or MBP plus anti–IL-10
receptor mAb. One representa-
tive experiment out of three is shown. (B) CD41 T cells were purified
and stimulated in vitro with MBP plus irradiated T cell–depleted spleno-
cytes from control CSJLF1/J mice for 60 h. The amount of IFN-g in the
supernatants was measured by ELISA. One representative experiment out
of two is shown. The results are the mean of three or four individual
mice/group 6 SEM.
Figure 5. hIL-10Tg mice on the IL-10KO genetic background are
EAE resistant. (A) Peak severity scores of individual mice treated with
isotype control mAb or anti–hIL-10 mAb (1 mg/dose) on days 0, 7, and
14. Results shown are compiled from two separate experiments. (B) Av-
erage severity score over time for the three groups of mice shown in A.
Figure 6. Histology of spinal cords of hIL-10Tg mice on the IL-10KO
background shown in Fig. 5. (A) NonTg IL-10KO mice were EAE sus-
ceptible and showed inflammatory infiltrates and plaques of demyelination
in spinal cords (arrowheads). (B) hIL-10Tg IL-10KO mice were EAE
resistant and their spinal cords showed no inflammatory infiltrates or de-
myelination. Luxol fast blue stain with hematoxylin counterstain. 3125. 
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Several observations suggest that myelin-reactive Th1
cells are induced in hIL-10Tg mice despite the absence of
disease. Similar levels of IFN-
 
g
 
 were produced by purified,
MBP-specific CD4
 
1
 
 cells from EAE-resistant hIL-10Tg
mice and EAE-susceptible nonTg littermates when stimu-
lated in vitro with wild-type APC and MBP (Fig. 4). No
MBP-induced IL-4 was produced by T cells from Tg or
nonTg mice, suggesting that EAE resistance was not associ-
ated with a Th2 response. These results are consistent with
a report showing that, although systemic treatment with
rIL-10 decreased the severity of EAE in SJL mice, PLP-
specific Th1 cells were induced and no PLP-specific Th2
cells were found (9). These data are also in agreement with
the original finding that IL-10 does not substantially inhibit
the development of Th1 cells but does inhibit their effector
function (1, 19).
EAE in BALB/c and SJL 
 
3
 
 BALB/c F1 mice is charac-
terized by an intense inflammatory infiltrate found pre-
dominantly in the white matter of the CNS and occasion-
ally extending into the gray matter region, causing neuronal
destruction and death (not shown). The absence of an in-
flammatory infiltrate in the CNS of EAE-resistant Tg mice
(Figs. 2 and 6) suggests that either autoreactive T cells did
not enter the CNS or the few T cells entering the CNS
were not able to recruit additional inflammatory cells. In
vitro, IL-10 has been shown to inhibit antigen presentation
and production of IL-1, IL-6, TNF-
 
a
 
, CD80, and CD86
by LPS- and/or IFN-
 
g
 
–activated microglia (20, 21).
Therefore, it is possible that IL-10Tg in the CNS may in-
hibit microglia antigen presentation and activation of mye-
lin-reactive Th1 cells.
Several parameters, including the amount of IL-10 and
the mode of gene regulation in specific local regions, may
account for the effectiveness of IL-10Tg in inhibition of
EAE. hIL-10 was detectable in the serum of the hIL-10Tg
mice at levels of 400–700 pg/ml (13). In vitro, hIL-10 and
mouse IL-10 were detected in the lymph node cell cultures
at similar levels of 2–6 ng/ml (data not shown). Thus,
IL-10Tg was not present systemically at high levels even
though it significantly protected mice from EAE.
Two separate studies have shown that IL-10 regulated by
lymphocyte-specific promoters can inhibit EAE. Adoptive
transfer of PLP-specific memory T cells expressing IL-2
promoter–regulated IL-10 partially reduced or reversed
disease in PLP-immunized recipient mice (12). FVB 
 
3
 
 SJL
F1 mice expressing Tg murine IL-10 under the lympho-
cyte-specific CD2 promoter are resistant to EAE induced
by PLP immunization (22). These results and the findings
in the present study suggest that, in addition to lympho-
cyte-derived IL-10, MHC class II–positive cell-derived
IL-10Tg, which may be upregulated early in an inflamma-
tory response, can dramatically protect mice from EAE.
Furthermore, our preliminary results show that adoptive
transfer of MBP-specific encephalitogenic Th1 cells can
not induce EAE in hIL-10Tg mice, suggesting a role for
local inhibition of Th1 cells by MHC class II promoter-
regulated IL-10Tg within the CNS (data not shown).
These studies suggest that IL-10, applied with appropriate
localization, in appropriate amounts, and at the appropriate
time, can completely protect animals from EAE, despite
their generation of potentially pathogenic Th1-like cells.
This model should permit a more detailed understanding of
the conditions necessary for IL-10 inhibition of autoim-
mune-mediated CNS inflammation, as this insight will pro-
vide information about how to use IL-10 in therapeutic
situations.
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